TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05359653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate
Description: 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate
Description: 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched sugar tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched sugar tablet
Study: NCT05660941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Ultra rapid Lispro

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro
Description: Conventional Lispro
Study: NCT06099249

Intervention type: DEVICE
Intervention: ASUS ECG App
Description: The procedure will commence with instructing the participants to become acquainted with the ASUS ECG App. Following this introduction, participants will be asked to sit quietly for a 5-minute resting period before undergoing a 12-lead ECG recording, which will last for approximately 30 seconds. The participant will be guided to simultaneously record a separate single-lead ECG using the ASUS ECG App. Both data streams will be synced together by the Study Staff. Each participant will undergo a total of three trials involving the simultaneous recording of a 12-lead ECG and a single-lead ECG using the ASUS ECG App.

Intervention type: DEVICE
Intervention: ASUS ECG App
Description: The procedure will commence with instructing the participants to become acquainted with the ASUS ECG App. Following this introduction, participants will be asked to sit quietly for a 5-minute resting period before undergoing a 12-lead ECG recording, which will last for approximately 30 seconds. The participant will be guided to simultaneously record a separate single-lead ECG using the ASUS ECG App. Both data streams will be synced together by the Study Staff. Each participant will undergo a total of three trials involving the simultaneous recording of a 12-lead ECG and a single-lead ECG using the ASUS ECG App.
Study: NCT06239012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Position measurement with BePow
Description: 14 measurements taken with the device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Position measurement with MCPAA scale
Description: MCPAA : measurement of seated postural control in adults in French 12 measurements taken with the goniometer
Study: NCT05566288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg tablets
Study: NCT04777318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: A total of 12 sessions of conventional physiotherapy program for 4 weeks were applied 3 days a week. The conventional physiotherapy program included 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy and Muscle Energy Technique
Description: In addition to conventional therapy, the muscle energy technique was applied to the individuals in the second group at the same frequency. Muscle energy technique was applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle was applied as one set (each set includes three repetitions). The patient was asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the restriction was felt. After the application, the patient was asked to breathe and relax, and the neck was brought back to the barrier point and the technique was repeated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy and Cervical Mobilization Techniques
Description: Cervical mobilization techniques were also applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques were applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques were applied. Vertebrobasilar InsufficiencyTest was applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage was applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
Study: NCT05041998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-femoral prosthetic socket
Description: Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~1. Soft socket (Socket made from softer material than unmodified original)~2. Stiff socket (Socket made from stiffer material than unmodified original)~3. moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~4. slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~5. Oversized socket (The socket volume is 6% larger than the unmodified original)~6. Undersized socket (The socket volume is 6% smaller than the unmodified original)~7. CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~8. MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)
Study: NCT05190653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative and supportive care
Description: The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
Study: NCT05532059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, tislelizumab, gemcitabine and cisplatin
Description: Lenvatinib, tislelizumab, gemcitabine and cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and cisplatin
Description: gemcitabine and cisplatin
Study: NCT04997941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Oral Product
Description: Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Oral Product
Description: Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Ki-67
Description: Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of Ki-67
Description: Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
Study: NCT06292663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The subjects get a supplement of information via. a Vitual Reality (VR) headset. The information they get through the VR headset is about their course on the day of their surgery.
Study: NCT04304079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARssist system
Description: As stated in ARssist system arm description
Study: NCT05065073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol
Description: Iso-osmolar Contrast Media

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol
Description: Iso-osmolar Contrast Media

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol
Description: Low-Osmolar Contrast Media

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol
Description: Low-Osmolar Contrast Media
Study: NCT06029062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS Sham
Description: Sham tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS Sham
Description: Sham tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS Sham
Description: Sham tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 10Hz
Description: 10Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 10Hz
Description: 10Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 10Hz
Description: 10Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 20Hz
Description: 20Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 20Hz
Description: 20Hz tACS will applied to the brain through the scalp for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 20Hz
Description: 20Hz tACS will applied to the brain through the scalp for 20 minutes.
Study: NCT04806633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 5mg
Description: Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this arm will receive placebo.
Study: NCT04997941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
Study: NCT06187493

Intervention type: DRUG
Group type: OTHER
Intervention: lisinopril, enalapril
Description: 1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia.

Intervention type: DRUG
Group type: OTHER
Intervention: dapagliflozin, empagliflozin
Description: 1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia.
Study: NCT05172466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeCare application
Description: Participants will complete activities on the application 3 times a week for 2 weeks when they first join the study. They will then attend 4 in-person visits where they complete clinical and application based assessments. Activities are clearly marked in the application and participants are assigned specific assessments by the study team. The application analyzes user input during each evaluation to provide an outcome measure for that assessment.
Study: NCT05353283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Counselling
Description: Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-care Urine Tenofovir Measurement
Description: Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
Study: NCT06169163

Intervention type: OTHER
Intervention: Exhaled breath sampling
Description: Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.

Intervention type: OTHER
Intervention: Exhaled breath sampling
Description: Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.
Study: NCT05301413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Diabetes Prevention Program
Description: This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts
Study: NCT05102292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: HLX208 450mg bid po
Study: NCT04914156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic based dietary advice
Description: Genetic test results for 70 genes relating to nutrition and physical activity will be used in conjunction with participants current dietary intake to create nutrition advice tailored to each individual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalised population based dietary advice
Description: Current dietary intake will be compared with current best practice population-based sports nutrition dietary advice to create tailored nutrition advice for each of the participants
Study: NCT06507579

Intervention type: DEVICE
Intervention: Hydra transcatheter aortic valve (THV) series
Description: The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
Study: NCT05222399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3871801
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3871801
Description: Administered orally.
Study: NCT05301413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Diabetes Prevention Program
Description: This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored DPP Enhanced with Socioeconomic Supports
Description: This intervention includes the culturally tailored DPP curriculum, class procedures, and handouts along with promotional items for class participation, opportunities to attend class in-person or virtually through a digital platform, and assistance from a community health worker to provide linkage to health care services and community resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: This is the CDC TD2 evidence-based Diabetes Prevention Program
Study: NCT06484634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
Study: NCT04701112

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary His bundle pacing
Description: Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary His bundle pacing
Description: Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration.
Study: NCT05301413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: This is the CDC TD2 evidence-based Diabetes Prevention Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: This is the CDC TD2 evidence-based Diabetes Prevention Program
Study: NCT05619120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
Study: NCT05582044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-body Negative Pressure (-25 mmHg)
Description: The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
Study: NCT06287255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIM+
Description: The Exercise is Medicine (EIM) program involves a personalized exercise prescription and wellness coaching component. At the first 1:1 session, participants are provided with a Fitbit and onboarded with Fitabase, allowing for documentation of baseline health behaviors. Over the course of the program, the EIM fitness specialist reviews Fitbit data and progress towards goals, sending push notifications for encouragement and reminders. A personal training session is conducted, followed by sixteen group sessions including up to eight participants. The final session includes updating goals, incorporating Fitbits, and providing an updated exercise prescription. Upon program completion, participants will attend monthly webinars and health coaching sessions at 6- and 12-months post-program. The program aims to help individuals overcome barriers and maintain long-term exercise self-efficacy.